Smith & Nephew

Smith & Nephew has revealed in-vitro study results suggesting ACTICOAT Silver-Coated Antimicrobial Dressings are bactericidal against some antibiotic resistant organisms carrying the NDM-1 enzyme, often referred to as ‘superbugs’.

Buying one’s distributor is not uncommon in the medical device business, and can be a good thing for all parties. Smith and Nephew’s acquisition of PCE should give it greater control of market activities in Brazil…. and higher margins.

Smith & Nephew plc has completed the acquisition of substantially all the assets of Healthpoint Biotherapeutics for $782 million in cash, financed from Smith & Nephew’s existing cash resources and bank facilities.

Smith & Nephew plc is so keen to cement its place in wound care that it is acquiring bioactive debridement specialist company Healthpoint Biotherapeutics for $782 million in cash, which is reportedly over 4x revenue and 71x earnings.

Smith & Nephew plc has announced the appointment of Julie Brown as Chief Financial Officer. She will formally take up the post by early February 2013, when she will also be appointed to the Board as an Executive Director.

Sports med and Negative Pressure Wound Therapy are the only stars in the portfolio last quarter for Smith & Nephew, although profit performance strength suggests restructuring and disposals have kicked in.

Smith & Nephew has chosen to announce the launch of its Trigen™ Low-Profile Screw at this week’s Orthopaedic Trauma Association meeting in Minneapolis. In a press release it says Trigen is the only truly “captured” head, low-profile screw on the market.

Smith & Nephew has announced the launch of its Legion™ HK Hinge Knee implant to surgeons in the US and Canada. As the first hinged knee to be designed using normal knee kinematics, the implant provides a new option for those patients facing difficult primary or revision knee surgery.

Smith & Nephew has announced that the UK’s National Institute for Health and Clinical Excellence (NICE) has issued draft guidance supporting the case for utilising the Exogen Ultrasound Bone Healing System. It’s now putting its draft findings out for consultation.

Financial key performance indicators for S&N’s quarter, when set against the equivalent period a year ago show revenue of $1,029 million, up 2% on an underlying basis, trading profit of $234 million, up 6% on an underlying basis, with trading profit margin up 80 bps to 22.7% as Advanced Surgical Devices (ASD) division restructuring benefits come through

Smith & Nephew had already issued a Field Safety Notice on its R3 metal acetabular liner. Now MHRA has followed up with its issuance of a Medical Device Alert including direction on patient follow-up.

Smith & Nephew has announced the launch of its Truclear 5.0 System, according to the company the smallest hysteroscopic morcellator system to receive FDA 510(k) clearance. The company claims its system’s smaller size now provides surgeons with the potential of using it in the office setting.

Smith & Nephew is withdrawing a component of one of its all-metal artificial hip systems following a higher than normal level of patient problems with the device. The fact that the recall was provoked by clinical outcome data points to the potential power of implant registries in regulating surgical implants.

Smith & Nephew, Inc. acquires Kalypto Medical, Inc., further investing in Negative Pressure Wound Therapy to deliver continual innovation

You’d have thought ligament fixation device design had been done to death, but marginal benefits still count in what is a sizeable market, so Smith & Nephew’s new “open architecture” anchor should find customers. After twenty years of anchors, quite what a shoulder surgeon might be so dissatisfied with that this new device addresses is beyond us, but it looks a smart enough idea.

After being available for over ten years internationally, Smith & Nephew finally introduced its POLARCUP Dual Mobility Hip System to orthopaedic surgeons in the US.